LifeMD appoints William Febbo (OptimizeRx CEO) to Board; Galluppi resigns as director

LifeMD, Inc.

Stefan Galluppi resigns from Board effective June 20, 2023; no disagreement; continues as Chief Innovation Officer.
William Febbo appointed to Board; receives 75,000 restricted shares (half vest immediately) and 37,500 stock option.
Febbo also entered consulting agreement May 30 for 375,000 restricted shares vesting quarterly through Nov 2024.
Febbo is CEO of OptimizeRx (OPRX) with 25+ years in healthcare and digital health.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stefan Galluppi

Director

LFMD · LifeMD, Inc.

Effective: 2023-06-20
Filed: June 22, 2023, 7:59 PM ET

On June 20, 2023, Stefan Galluppi resigned from the Board of Directors of LifeMD, Inc. (the "Company") effective immediately.

Appointed

William J. Febbo

Director

LFMD · LifeMD, Inc.

Effective: 2023-06-20
Filed: June 22, 2023, 7:59 PM ET

On June 20, 2023, William J. Febbo was appointed to the Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stefan Galluppi resigned as Director at LifeMD, Inc..

Action: resigned
Role: Director

Exact text from the filing

On June 20, 2023, Stefan Galluppi resigned from the Board of Directors of LifeMD, Inc. (the "Company") effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

William J. Febbo was appointed as Director at LifeMD, Inc..

Action: appointed
Role: Director

Exact text from the filing

On June 20, 2023, William J. Febbo was appointed to the Board of Directors.

View on SEC.gov

LifeMD, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-022145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.